
|Articles|November 15, 2021
Emmes and MedGenome Launch Genomics Strategic Rare Disease Research Partnership
Advertisement
Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced a partnership with MedGenome powered by human genomics, for rare disease patients.
The two companies will collaborate to combine patients' epidemiologic, phenotypic, and genomic data into custom disease registries aiming to enhance study design, support patient recruitment, and create standard control arms for advanced statistical models of treatment effect.
Some of the initial rare diseases that the Emmes/MedGenome partnership will address include hemophilia, Duchenne muscular dystrophy and muscular atrophies, and retinitis pigmentosa.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5



